- Home
- SPTX vs NBXG Comparison
SPTX vs NBXG Comparison
Compare SPTX & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPTX | NBXG |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPTX | NBXG |
|---|---|---|
| Price | $21.25 | $16.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 206.6K | ★ 243.2K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.59 | $12.32 |
| 52 Week High | $22.98 | $17.43 |
Technical Indicators
Market Signals| Indicator | SPTX | NBXG |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 51.00 |
| Support Level | $17.89 | $15.45 |
| Resistance Level | $21.59 | $17.19 |
| Average True Range (ATR) | 1.88 | 0.50 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 68.80 | 32.75 |
Price Performance
Historical ComparisonAbout SPTX Seaport Therapeutics Inc. Common Stock
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.